Michel Rivoire
Papers
1
Total Citations
14
H-Index
1
About
Michel Rivoire is a leading surgical oncologist whose work has fundamentally shaped the management of rectal cancer, particularly through organ-preserving strategies. His primary research focuses on optimizing neoadjuvant radiochemotherapy protocols and refining surgical approaches to avoid permanent colostomy. Rivoire’s landmark contribution is the GRECCAR 2 randomized phase 3 trial, which compared local excision versus total mesorectal excision in patients with T2-T3 low rectal cancer who showed a good response to neoadjuvant treatment. This pivotal study, cited over 140 times, provided critical evidence that local excision can be a safe alternative in carefully selected patients, sparing them the morbidity of radical surgery. Beyond this trial, his work has advanced the understanding of sphincter-saving techniques and the role of chemoradiation in downstaging tumors. Rivoire’s research has directly influenced clinical guidelines and improved quality of life for thousands of patients. His ongoing investigations continue to refine patient selection criteria, pushing the boundaries of minimally invasive, function-preserving rectal cancer surgery.
Research Focus
Key Achievements
Top Papers
- 1